{"title":"对慢性 HBV 感染妇女产后复发进行抗病毒治疗可缩短谷丙转氨酶恢复时间并降低 4 年内肝炎复发率。","authors":"Min Quan, Cong Liu, Wei Li, Hui-Chun Xing","doi":"10.1155/2022/4753267","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Few studies explored whether anti-hepatitis B virus (HBV) therapy should be initiated during postpartum hepatitis flare.</p><p><strong>Aim: </strong>This study aimed to analyze the effect of anti-HBV therapy on postpartum hepatitis flare and evaluate the prognosis within 4 years postpartum.</p><p><strong>Methods: </strong>This retrospective study enrolled hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen (HBeAg)-positive pregnant women with HBV DNA ≥ 10<sup>6</sup> IU/mL. A total of 152 pregnant women were included: 103 in the prophylactic anti-HBV therapy group (PT-G) and 49 in the non-prophylactic anti-HBV therapy group (NPT-G). The women with a postpartum flare were assigned to the anti-HBV therapy group (AT-G) and non-anti-HBV therapy group (NAT-G) to analyze the effect of postpartum anti-HBV therapy on hepatitis flare. Virological and biochemical parameters were assessed.</p><p><strong>Results: </strong>Taking postpartum 12 weeks as the cutoff point, the ALT recovered time for postpartum flare women is shorter in AT-G (<i>n</i> = 16, 42.1%) or PT-G (<i>n</i> = 23, 34.8%) than in NAT-G (<i>n</i> = 14, 23.0%; <i>x</i> <sup>2</sup> = 4.067, <i>P</i>=0.044) or NPT-G (<i>n</i> = 4, 11.1%; <i>x</i> <sup>2</sup> = 5.579, <i>P</i>=0.018). Taking postpartum 26 weeks as the cutoff point, the ALT recovered time is shorter in AT-G (<i>n</i> = 35, 57.3%) or PT-G (<i>n</i> = 44, 66.7%) than in NAT-G (<i>n</i> = 32, 84.2%; <i>x</i> <sup>2</sup> = 7.707, <i>P</i>=0.006) or NPT-G (<i>n</i> = 16, 44.4%; <i>x</i> <sup>2</sup> = 4.749, <i>P</i>=0.029). Postpartum flare recovery time was positively correlated with HBV DNA level at delivery [<i>r</i> = 0.223, <i>P</i>=0.025, 95%CI (0.022～0.41)]. The hepatitis re-flare rates within postpartum 4 years in AT-G (<i>n</i> = 3, 9.68%) is lower than that in NAT-G (<i>n</i> = 24, 45.4%; <i>x</i> <sup>2</sup> = 14.003, <i>P</i> ≤ 0.001). The HBeAg, HBsAg, HBV DNA, and ALT level at postpartum 4 years in AT-G were lower than that in NAT-G (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Anti-HBV therapy for postpartum hepatitis flare of women with chronic HBV could shorten the ALT recovery time and reduce hepatitis re-flare rates within 4 years of postpartum.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":" ","pages":"4753267"},"PeriodicalIF":2.7000,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236834/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antiviral Therapy for a Postpartum Flare in Women with Chronic HBV Infection Shortens the ALT Recovery Time and Reduces Hepatitis Re-Flare Rates within 4 years.\",\"authors\":\"Min Quan, Cong Liu, Wei Li, Hui-Chun Xing\",\"doi\":\"10.1155/2022/4753267\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Few studies explored whether anti-hepatitis B virus (HBV) therapy should be initiated during postpartum hepatitis flare.</p><p><strong>Aim: </strong>This study aimed to analyze the effect of anti-HBV therapy on postpartum hepatitis flare and evaluate the prognosis within 4 years postpartum.</p><p><strong>Methods: </strong>This retrospective study enrolled hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen (HBeAg)-positive pregnant women with HBV DNA ≥ 10<sup>6</sup> IU/mL. A total of 152 pregnant women were included: 103 in the prophylactic anti-HBV therapy group (PT-G) and 49 in the non-prophylactic anti-HBV therapy group (NPT-G). The women with a postpartum flare were assigned to the anti-HBV therapy group (AT-G) and non-anti-HBV therapy group (NAT-G) to analyze the effect of postpartum anti-HBV therapy on hepatitis flare. Virological and biochemical parameters were assessed.</p><p><strong>Results: </strong>Taking postpartum 12 weeks as the cutoff point, the ALT recovered time for postpartum flare women is shorter in AT-G (<i>n</i> = 16, 42.1%) or PT-G (<i>n</i> = 23, 34.8%) than in NAT-G (<i>n</i> = 14, 23.0%; <i>x</i> <sup>2</sup> = 4.067, <i>P</i>=0.044) or NPT-G (<i>n</i> = 4, 11.1%; <i>x</i> <sup>2</sup> = 5.579, <i>P</i>=0.018). Taking postpartum 26 weeks as the cutoff point, the ALT recovered time is shorter in AT-G (<i>n</i> = 35, 57.3%) or PT-G (<i>n</i> = 44, 66.7%) than in NAT-G (<i>n</i> = 32, 84.2%; <i>x</i> <sup>2</sup> = 7.707, <i>P</i>=0.006) or NPT-G (<i>n</i> = 16, 44.4%; <i>x</i> <sup>2</sup> = 4.749, <i>P</i>=0.029). Postpartum flare recovery time was positively correlated with HBV DNA level at delivery [<i>r</i> = 0.223, <i>P</i>=0.025, 95%CI (0.022～0.41)]. The hepatitis re-flare rates within postpartum 4 years in AT-G (<i>n</i> = 3, 9.68%) is lower than that in NAT-G (<i>n</i> = 24, 45.4%; <i>x</i> <sup>2</sup> = 14.003, <i>P</i> ≤ 0.001). The HBeAg, HBsAg, HBV DNA, and ALT level at postpartum 4 years in AT-G were lower than that in NAT-G (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Anti-HBV therapy for postpartum hepatitis flare of women with chronic HBV could shorten the ALT recovery time and reduce hepatitis re-flare rates within 4 years of postpartum.</p>\",\"PeriodicalId\":48755,\"journal\":{\"name\":\"Canadian Journal of Gastroenterology and Hepatology\",\"volume\":\" \",\"pages\":\"4753267\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2022-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236834/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Gastroenterology and Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/4753267\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/4753267","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Antiviral Therapy for a Postpartum Flare in Women with Chronic HBV Infection Shortens the ALT Recovery Time and Reduces Hepatitis Re-Flare Rates within 4 years.
Background: Few studies explored whether anti-hepatitis B virus (HBV) therapy should be initiated during postpartum hepatitis flare.
Aim: This study aimed to analyze the effect of anti-HBV therapy on postpartum hepatitis flare and evaluate the prognosis within 4 years postpartum.
Methods: This retrospective study enrolled hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen (HBeAg)-positive pregnant women with HBV DNA ≥ 106 IU/mL. A total of 152 pregnant women were included: 103 in the prophylactic anti-HBV therapy group (PT-G) and 49 in the non-prophylactic anti-HBV therapy group (NPT-G). The women with a postpartum flare were assigned to the anti-HBV therapy group (AT-G) and non-anti-HBV therapy group (NAT-G) to analyze the effect of postpartum anti-HBV therapy on hepatitis flare. Virological and biochemical parameters were assessed.
Results: Taking postpartum 12 weeks as the cutoff point, the ALT recovered time for postpartum flare women is shorter in AT-G (n = 16, 42.1%) or PT-G (n = 23, 34.8%) than in NAT-G (n = 14, 23.0%; x2 = 4.067, P=0.044) or NPT-G (n = 4, 11.1%; x2 = 5.579, P=0.018). Taking postpartum 26 weeks as the cutoff point, the ALT recovered time is shorter in AT-G (n = 35, 57.3%) or PT-G (n = 44, 66.7%) than in NAT-G (n = 32, 84.2%; x2 = 7.707, P=0.006) or NPT-G (n = 16, 44.4%; x2 = 4.749, P=0.029). Postpartum flare recovery time was positively correlated with HBV DNA level at delivery [r = 0.223, P=0.025, 95%CI (0.022～0.41)]. The hepatitis re-flare rates within postpartum 4 years in AT-G (n = 3, 9.68%) is lower than that in NAT-G (n = 24, 45.4%; x2 = 14.003, P ≤ 0.001). The HBeAg, HBsAg, HBV DNA, and ALT level at postpartum 4 years in AT-G were lower than that in NAT-G (P < 0.001).
Conclusion: Anti-HBV therapy for postpartum hepatitis flare of women with chronic HBV could shorten the ALT recovery time and reduce hepatitis re-flare rates within 4 years of postpartum.
期刊介绍：
Canadian Journal of Gastroenterology and Hepatology is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of gastroenterology and liver disease - medicine and surgery.
The Canadian Journal of Gastroenterology and Hepatology is sponsored by the Canadian Association of Gastroenterology and the Canadian Association for the Study of the Liver.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
